AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

San Diego-based Capstan is developing a potential first-in-class therapy to treat certain autoimmune disease by changing ...

AbbVie (ABBV) on Monday announced that it has entered into a definitive agreement to acquire privately held clinical-stage biotechnology company Capstan Therapeutics, Inc., in a bid to boost its ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

In the fight against cancer, immunotherapy—which aims to boost the body's natural defenses against cancer—is experiencing ...

A letter to the US public on the AMA website, signed by 75+ medical societies, stresses the vital importance of influenza, RSV, and COVID-19 vaccines.

One of the top school districts nationwide celebrated 611 students at its 67th annual commencement ceremony this month.

At baseline, eligible participants were randomized 4:1 to receive intravenous ARGX-119 or placebo ... and Associate Professor Maartje Huijbers from LUMC. argenx is a global immunology company ...

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site ...